From 2020 to 2035, the North America medical automation market exhibits significant revenue growth. In 2025, the market size is projected to reach 16,800 million USD. The trajectory thereafter shows accelerated adoption favored by digital transformation, with market revenue expected to scale up to 42,510 million USD by 2035. This robust growth is attributed to greater investments in automation, wider application breadth, and an uptick in AI and robotics across healthcare environments. Continuous product launches and adoption in both public and private settings have set the market on a steady upward trend.

Read More - https://bussinessinsights.com/research-report/north-america-medical-automation-market

Diagnostics & monitoring applications are projected to make up 35% of the total North America medical automation market in 2025, leading over therapeutics at 29%. Lab automation and pharmacy automation follow, together holding a significant market share due to progression in digital labs and pharmacy workflow automation. Medical logistics and training applications round out the application spectrum, supported by new training technologies and logistics automation. The dominance of diagnostics & monitoring reflects the regional priority on early disease detection and reliable, real-time patient monitoring solutions, as seen in major hospital networks and outpatient care centers across the US and Canada.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-medical-automation-market

Frequently Asked Questions

Who are the key players in North America Medical Automation Market industry?
The top 5 players in the North America Medical Automation Market are Siemens Healthineers, GE Healthcare, Stryker Corporation, Medtronic plc, and Becton Dickinson (BD). These companies lead by offering advanced automation solutions focusing on laboratory, pharmacy, diagnostics, and surgical automation technologies in healthcare settings.

What is the North America Medical Automation Market growth?
The North America Medical Automation Market has witnessed significant growth, driven by increasing demand for automation in diagnostic procedures. For example, in 2023, Siemens Healthineers reported a surge in demand for automated laboratory solutions, contributing to robust regional market expansion.

Which segment accounted for the largest North America Medical Automation Market share?
The diagnostics and monitoring segment holds the largest share in the North America Medical Automation Market. Automated laboratory diagnostics, particularly in blood testing and molecular diagnostics, have seen significant uptake, boosting efficiency and accuracy in hospitals and clinics across the region.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America Genotyping Assay Market has shown consistent revenue growth from 2020 to 2025, with projections indicating accelerated expansion through 2035. Revenue generation is primarily fueled by increased investment in precision medicine, rapid adoption of novel genotyping techniques, and expanding demand from agriculture and animal genetics sectors. The market is anticipated to achieve a strong CAGR between 2025 and 2035, with a growing inclination towards high-complexity assays and integrated solutions. This positive trajectory underscores North America’s role as a key player in genomic innovation and application.

Read More - https://bussinessinsights.com/research-report/north-america-genotyping-assay-market

Pharmacogenomics leads the North America Genotyping Assay Market by application in 2025, reflecting surging demand for personalized and precision medicine. Diagnostic research follows closely, driven by a rising prevalence of genetic disorders, cancer, and infectious diseases that necessitate targeted diagnostic tools. Agricultural biotechnology occupies a significant share as genotyping assays address the critical need for crop and livestock genetic optimization. The expansion of these applications is supported by robust investments, ongoing scientific advancements, and collaboration between industry and academia, accelerating innovation and market penetration throughout the region.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-genotyping-assay-market

Thanks & Regards,
Priya
sales@bussinessinsights.com

From 2020 to 2035, the North America Protein Engineering Market experiences robust, steady growth driven by increased investment in healthcare R&D, new biologic drug launches, and breakthroughs in computational protein science. Revenue in 2021 stood at 3,200 Million, expanding to 4,150 Million by 2025. The forecast projects continued momentum, reaching 8,950 Million in 2035. Contributing factors include the proliferation of protein therapeutics, enzyme applications in industry, and the evolution of high-throughput screening tools. The market's upward trajectory reflects growing confidence in protein engineering to address complex health and industrial challenges across the continent.

Read More - https://bussinessinsights.com/research-report/north-america-protein-engineering-market

Therapeutic applications dominate the North American protein engineering landscape in 2025, attributing their growth to increasing adoption of biologics and protein therapies. Industrial applications occupy the second largest share, highlighting the role of engineered enzymes in sectors ranging from food processing to detergents. Research usage also comprises a significant slice of the market, supported by intensive academic and commercial R&D investments to discover novel proteins for diverse applications.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-protein-engineering-market

Frequently Asked Questions

Who are the key players in North America Protein Engineering Market industry?
The top five players in the North America Protein Engineering Market are Thermo Fisher Scientific, Agilent Technologies, Genscript Biotech Corporation, Amgen Inc., and Bruker Corporation. These companies lead the industry through their advanced research capabilities, technological innovations, strong product portfolios, and widespread collaborations with research institutions.

What is the North America Protein Engineering Market growth?
The North America Protein Engineering Market has witnessed robust growth, with a CAGR of over 10% in recent years. Key drivers include increased investment in drug discovery and the launch of novel biologics, such as Amgen’s advancements in therapeutic proteins for rare diseases.

Which segment accounted for the largest North America Protein Engineering Market share?
Therapeutics segment dominates the North America Protein Engineering Market, holding the largest market share. This is due to the rising demand for engineered proteins in the treatment of chronic diseases like cancer and diabetes, and the continued development of monoclonal antibodies and enzyme therapies.

Thanks & Regards,
Priya
sales@bussinessinsights.com

Market revenue for North America thyroid function tests shows steady growth over the forecast period, rising from an estimated USD 1,580 Million in 2020 to USD 3,210 Million in 2035. This growth is supported by increasing thyroid disorder diagnoses, rising diagnostic awareness, and ongoing expansion in healthcare infrastructure. Significant investments in R&D and new product launches by leading companies are anticipated to further drive revenue upwards through the forecast horizon.

Read More - https://bussinessinsights.com/research-report/north-america-thyroid-function-test-market

Hypothyroidism is the leading application segment in the North America thyroid function test market for 2025, reflecting the high prevalence and clinical focus on underactive thyroid. Hyperthyroidism and thyroid cancer represent significant shares, driven by targeted screening and long-term patient monitoring. Autoimmune thyroid disease and goiter remain crucial applications, especially as diagnostic tools become more advanced. Expanding test access and increasing awareness campaigns designed for specific thyroid conditions are expected to further shape application trends across the region.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-thyroid-function-test-market

Frequently Asked Questions

Who are the key players in North America Thyroid Function Test Market industry?
Key players include Abbott Laboratories, LabCorp, Quest Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. These companies are recognized for their advanced diagnostic solutions, broad test menus, strong distribution networks, and ongoing investments in research and development to drive innovation and expand their product portfolios in the thyroid function testing space.

What is the North America Thyroid Function Test Market growth?
The North America Thyroid Function Test Market is experiencing steady growth, with recent estimates indicating a CAGR of around 5% through 2028. Growth is driven by rising thyroid disorder prevalence and innovations in diagnostic technologies from companies such as Abbott Laboratories and Quest Diagnostics.

Which segment accounted for the largest North America Thyroid Function Test Market share?
The hospital segment accounted for the largest share of the market. Hospitals offer comprehensive diagnostic capabilities and faster turnaround times, supported by well-established infrastructure. Increased patient inflow for screening and confirmatory tests further supports this segment's dominance, making hospitals the largest end-user for thyroid function testing in North America.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The total revenue of the North America Mycoplasma Testing Market is projected to grow steadily from 2020 to 2035. In 2021, the market achieved revenue of $391 million, reflecting growing adoption of advanced testing methods and regulatory compliance. The market is forecast to reach $980 million by 2030 before crossing the $1.25 billion mark by 2035. This progression highlights increasing demand from pharmaceutical, biotechnology, and academic institutions, driven by product innovation and diversified service offerings. The accelerated market expansion from 2025 onwards is attributed to further automation and digital integration into laboratory workflows.

Read More - https://bussinessinsights.com/research-report/north-america-mycoplasma-testing-market

Cell Line Testing dominates the application segment in the North America Mycoplasma Testing Market, making up 41% of the market share in 2025. Virus Testing follows with 22%, while End of Production Cell Testing takes 15%. The rapid expansion of research involving cell lines and the stringent requirement for cell-based therapeutic safety underpin the dominance of cell line testing applications. Diagnostic laboratories and academic/research institutions are significantly increasing their demand for mycoplasma detection to comply with quality and regulatory standards. The ongoing innovation in mycoplasma detection technologies is ensuring precise, high-throughput testing, particularly essential in virus and end-of-production cell testing scenarios.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-mycoplasma-testing-market

Thanks & Regards,
Priya
sales@bussinessinsights.com

The market has experienced steady revenue growth, rising from USD 1,360 Million in 2020 and projected to reach USD 3,890 Million by 2035. The upward trajectory is directly linked to increased adoption of molecular cytogenetic techniques in clinical and research applications, reinforced by expanding healthcare infrastructure and supportive regulatory environments across the United States, Canada, and Mexico.

Read More - https://bussinessinsights.com/research-report/north-america-molecular-cytogenetics-market

Cancer diagnosis accounts for the largest application segment in the North America Molecular Cytogenetics Market in 2025. Advances in cytogenetics have revolutionized oncology, enabling more accurate detection of chromosomal aberrations linked to various cancers. Genetic disorders comprise the next largest application due to the growing awareness and screening efforts for hereditary and congenital conditions. Personalized medicine continues to gain ground, with cytogenetics firmly embedded in therapeutic decision-making processes, especially for targeted therapies and precision oncology initiatives across North America.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-molecular-cytogenetics-market

Frequently Asked Questions

Who are the key players in North America Molecular Cytogenetics Market industry?
The top five players in the North America Molecular Cytogenetics Market are Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies, Illumina Inc., and PerkinElmer Inc. These companies are recognized for their comprehensive genetic analysis solutions, advanced technologies, and strong market presence, contributing significantly to molecular cytogenetics research and diagnostics.

What is the North America Molecular Cytogenetics Market growth?
The North America Molecular Cytogenetics Market has shown steady growth in recent years, primarily driven by increasing adoption of precision medicine and advances in genetic diagnostics. A notable example is Thermo Fisher Scientific, which reported significant expansion in their genetic testing portfolio, fueling market growth across hospitals and research centers in 2023.

Which segment accounted for the largest North America Molecular Cytogenetics Market share?
In terms of application, genetic disorder diagnosis holds the largest market share in the North America Molecular Cytogenetics Market. This is due to the increasing prevalence of genetic diseases and a growing demand for early and accurate diagnosis, allowing healthcare providers to manage and treat disorders more effectively.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North American ATP assays market has demonstrated robust growth, with revenue climbing from 350 Million in 2020 to an expected 510 Million in 2025. Projections indicate continued expansion, driven by new product innovations, broader application areas, and rising regulatory standards. The CAGR is expected to remain around 4.1% through 2035, signaling sustained industry demand across diagnostics, contamination testing, and research-driven sectors. The market’s financial trajectory reflects both organic industry maturation and the impact of advanced technological adoption.

Read More - https://bussinessinsights.com/research-report/north-america-atp-assays-market

Contamination testing leads ATP assay applications in North America, fueled by robust food safety regulations and pharmaceutical quality control protocols. Disease testing and drug discovery & development collectively contribute a notable market portion, propelled by increased R&D and heightened focus on novel diagnostics. Environmental testing has also grown, reflecting greater regulatory scrutiny and industrial monitoring needs. This landscape signals extended application diversity, with ATP-based protocols being integral across healthcare, industrial, and environmental safety verticals.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-atp-assays-market

Frequently Asked Questions

Who are the key players in North America ATP Assays Market industry?
The top 5 players in the North America ATP Assays Market include Thermo Fisher Scientific, Merck KGaA, Promega Corporation, PerkinElmer Inc., and BioThema AB. These companies offer a diverse range of ATP assay solutions for diagnostics, biotechnology research, and pharmaceutical applications and lead innovations in the region.

What is the North America ATP Assays Market growth?
The North America ATP Assays Market has witnessed notable growth in recent years, driven by rising adoption in clinical diagnostics and pharmaceutical research. In 2023, Thermo Fisher Scientific reported increased demand for ATP-based cell viability assays, positively impacting regional market expansion.

Which segment accounted for the largest North America ATP Assays Market share?
The disease testing segment held the largest market share in North America ATP Assays Market. This segment’s growth is supported by extensive use of ATP assays for infectious disease diagnostics, cancer research, and treatment monitoring, enabling more accurate and rapid identification of pathogens and cellular function.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America chromatography resin market in drug discovery is expected to demonstrate steady revenue growth from 2020 to 2035. Revenue reached 910 million in 2020, climbed to 1,175 million by 2025, and is forecast to surpass 2,950 million by 2035. This upward trajectory is propelled by increasing biopharmaceutical production, expanded drug discovery activities, and widespread adoption of advanced chromatography technologies. Continuous investments by major industry players and the introduction of innovative resin products further reinforce the robust financial outlook for the sector.

Read More - https://bussinessinsights.com/research-report/north-america-chromatography-resin-market-in-drug-discovery

Pharmaceutical & biotechnology companies are the primary users of chromatography resins, accounting for the largest market share in North America as of 2025. Academic & research institutes represent the second largest segment, reflecting the region’s advanced focus on fundamental R&D. Contract Research Organizations (CROs) and CMOs also play a key role, leveraging chromatography resins for outsourced drug discovery and development services. This distribution underscores the widespread adoption of resin-based purification across the entire drug discovery value chain.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-chromatography-resin-market-in-drug-discovery

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America urinalysis market is projected to grow from $1,650 million in 2020 to $3,450 million by 2035, at a CAGR of 6.2%. Consistent growth is attributed to the rising burden of chronic diseases, persistent technological advancements, and expanding adoption in both clinical and point-of-care settings. The period between 2025 and 2030 anticipates the fastest revenue acceleration, coinciding with widespread laboratory automation and broader reimbursement coverage for advanced diagnostic solutions. As healthcare infrastructure continues to modernize, demand for efficient and high-throughput urinalysis platforms will drive further market expansion.

Read More - https://bussinessinsights.com/research-report/north-america-urinalysis-market

Disease screening leads the application segment in the North America urinalysis market, reflecting the high prioritization of early detection protocols in healthcare systems. Pregnancy and fertility testing maintains significant demand due to ongoing advancements in reproductive health diagnostics. Drug testing remains a key segment, spurred by regulatory mandates and workplace health programs. The market also benefits from continued adoption in diabetes screening, kidney disease diagnostics, and UTI detection. This diverse application base, coupled with the proliferation of both clinical and point-of-care urinalysis, supports the upward revenue trajectory of the sector. Companies are developing multiplexed and integrated testing solutions to broaden clinical utility and operational efficiency.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-urinalysis-market

Frequently Asked Questions

Who are the key players in North America Urinalysis Market industry?
The top five players in the North America Urinalysis Market are Siemens Healthineers, Abbott Laboratories, F. Hoffmann-La Roche AG, Beckman Coulter (Danaher Corporation), and Sysmex Corporation. These companies lead the market with extensive diagnostic portfolios, advanced technology, and a strong geographic presence, driving innovation in urinalysis solutions.

What is the North America Urinalysis Market growth?
The North America Urinalysis Market is experiencing steady growth, estimated at a CAGR of over 7% from 2023–2028. Recent advancements, such as Abbott’s launch of next-generation urinalysis analyzers, and increased demand for automated diagnostic systems, are driving expansion and market penetration across healthcare settings.

Which segment accounted for the largest North America Urinalysis Market share?
The diagnostic laboratories segment holds the largest market share in the North America Urinalysis Market. This is due to the high volume of routine urinalysis tests performed in labs, increasing chronic disease cases, and adoption of automated systems that improve accuracy and workflow in clinical diagnostics.

Thanks & Regards,
Priya
sales@bussinessinsights.com

Market revenue for North America Molecular Quality Controls is projected to expand from $520 Million in 2020 to $980 Million by 2025, reaching beyond $2600 Million by 2035. Growth is propelled by increasing clinical application, regulatory enforcement, and digital transformation in diagnostics. The revenue trajectory reflects accelerated adoption post-pandemic, with robust investments in automation and precision diagnostics expected to sustain high single-digit CAGR throughout the forecast period.

Read More - https://bussinessinsights.com/research-report/north-america-molecular-quality-controls-market

In 2025, Infectious Disease remains the dominant application segment, owing to sustained post-pandemic surveillance and routine pathogen screening. Oncology follows closely due to rising cancer diagnostic rates and genetic testing for personalized medicine. Blood Screening holds a substantial share, reflecting rising demand for safe transfusions and early disease detection. The increasing importance of genetics, microbiology, and other applications underlines the broadening scope of molecular quality controls in North American healthcare.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-molecular-quality-controls-market

Thanks & Regards,
Priya
sales@bussinessinsights.com